Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Современные возможности лечения колоректального рака
Современные возможности лечения колоректального рака
Ю.А.Барсуков, В.И.Кныш. Современные возможности лечения колоректального рака. Онкология. 2006; 2: 7-16.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Vogel I, Soeth E, Ruder C et al. Disseminated tumor cells in the blood and/or bone marrow of patients with colorectal carcinoma are an independent prognostic factor. Ann. Oncol., 2000; 11 (suppl. 4): 43, abstr. 183.
2. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet, 1995 Apr 15;345(8955):939–44.
3. Haller D, Catalano PJ, Macdonald JS, Mayer RJ. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year final report of int-0089. Proc Am Soc Clin Oncol 1998; 17: 256a (Abstr 982).
4. Wolmark N, Rockette H, Mamounas E et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999; 17: 3553–9.
5. Andre T et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol, 2003 Aug 1;21(15):2896–903.
6. Grothey A et al. Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms. Med Klin, 2002 May 15;97(5):270–7.
7. S. Hensley Alford et al. Stage III colon cancer in the elderly: Adjuvant therapy and survival. Proc Am Soc Clin Oncol 2003 abstr 3008.
8. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097–106.
9. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282–92.
10. Cassidy J. et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a phase III trial. Proceedings ASCO 2004 abstract 3509.
11. Twelves C. et al. Capecitabine as adjuvant treatment for satge III colon cancer. N Engl J Med 2005; 352:269–704.
12. Joseph NE et al. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol. 2003 Apr;10(3):213–8.
13. Scheithauer W. et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial Annals of Oncology 14: 1735–1743, 2003.
2. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet, 1995 Apr 15;345(8955):939–44.
3. Haller D, Catalano PJ, Macdonald JS, Mayer RJ. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year final report of int-0089. Proc Am Soc Clin Oncol 1998; 17: 256a (Abstr 982).
4. Wolmark N, Rockette H, Mamounas E et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999; 17: 3553–9.
5. Andre T et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol, 2003 Aug 1;21(15):2896–903.
6. Grothey A et al. Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms. Med Klin, 2002 May 15;97(5):270–7.
7. S. Hensley Alford et al. Stage III colon cancer in the elderly: Adjuvant therapy and survival. Proc Am Soc Clin Oncol 2003 abstr 3008.
8. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097–106.
9. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282–92.
10. Cassidy J. et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a phase III trial. Proceedings ASCO 2004 abstract 3509.
11. Twelves C. et al. Capecitabine as adjuvant treatment for satge III colon cancer. N Engl J Med 2005; 352:269–704.
12. Joseph NE et al. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol. 2003 Apr;10(3):213–8.
13. Scheithauer W. et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial Annals of Oncology 14: 1735–1743, 2003.
Авторы
Ю.А.Барсуков, В.И.Кныш
НИИ КО ГУ РОНЦ РАМН им. Н.Н.Блохина, Москва
НИИ КО ГУ РОНЦ РАМН им. Н.Н.Блохина, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.